Facioscapulohumeral Disease as a myodevelopmental disease: Applying Ockham's razor to its various features.
暂无分享,去创建一个
[1] P. Zammit,et al. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies , 2022, European journal of translational myology.
[2] Dave W. Oyler,et al. Persistent Fibroadipogenic Progenitor Expansion Following Transient DUX4 Expression Provokes a Profibrotic State in a Mouse Model for FSHD , 2022, International journal of molecular sciences.
[3] S. Jagannathan. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy. , 2022, Biochimica et biophysica acta. Molecular basis of disease.
[4] K. Mamchaoui,et al. Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target , 2022, Redox biology.
[5] F. Magdinier,et al. Facioscapulohumeral dystrophy weakened sarcomeric contractility is mimicked in induced pluripotent stem cells‐derived innervated muscle fibres , 2021, Journal of cachexia, sarcopenia and muscle.
[6] M. Pannese,et al. DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy , 2021, Cells.
[7] F. Rossi,et al. Emerging skeletal muscle stromal cell diversity: Functional divergence in fibro/adipogenic progenitor and mural cell populations. , 2021, Experimental cell research.
[8] N. van Alfen,et al. Natural History of Facioscapulohumeral Dystrophy in Children , 2021, Neurology.
[9] P. Muñoz-Cánoves,et al. Muscle repair after physiological damage relies on nuclear migration for cellular reconstruction , 2021, Science.
[10] N. Voermans,et al. 1st FSHD European Trial Network workshop:Working towards trial readiness across Europe , 2021, Neuromuscular Disorders.
[11] B. Cairns,et al. p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models , 2021, Nature Genetics.
[12] C. Banerji,et al. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7 , 2021, EMBO molecular medicine.
[13] B. Chadwick,et al. CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy , 2021, Scientific Reports.
[14] A. Paulussen,et al. Facioscapulohumeral muscular dystrophy—Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease , 2021, Clinical genetics.
[15] V. Somers,et al. Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD) , 2021, Frontiers in Neurology.
[16] L. Joosten,et al. Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies , 2021, Journal of neuromuscular diseases.
[17] H. Deigner,et al. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update , 2021, Orphanet Journal of Rare Diseases.
[18] H. Clevers,et al. Tissue regeneration: Reserve or reverse? , 2021, Science.
[19] F. Dilworth,et al. Epigenetic regulation of satellite cell fate during skeletal muscle regeneration , 2021, Skeletal muscle.
[20] B. Brand-Saberi,et al. The CXCR4/SDF-1 Axis in the Development of Facial Expression and Non-somitic Neck Muscles , 2020, Frontiers in Cell and Developmental Biology.
[21] C. Horlings,et al. Characterizing the face in facioscapulohumeral muscular dystrophy , 2020, Journal of Neurology.
[22] Yi-Wen Chen,et al. DUX4 transcript knockdown with antisense 2'-O-methoxyethyl gapmers for the treatment of facioscapulohumeral muscular dystrophy. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] A. Heerschap,et al. Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy , 2020, Muscle & nerve.
[24] Ayellet V. Segrè,et al. The impact of sex on gene expression across human tissues , 2020, Science.
[25] H. Masumoto,et al. Damaged Myofiber-Derived Metabolic Enzymes Act as Activators of Muscle Satellite Cells , 2020, Stem cell reports.
[26] J. Jaiswal,et al. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy , 2020, International journal of molecular sciences.
[27] M. Kyba,et al. Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice. , 2020, The Journal of clinical investigation.
[28] S. Kuang,et al. Temporal Dynamics and Heterogeneity of Cell Populations during Skeletal Muscle Regeneration , 2020, iScience.
[29] K. Lim,et al. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy , 2020, International journal of molecular sciences.
[30] A. Heerschap,et al. Preserved single muscle fiber specific force in facioscapulohumeral muscular dystrophy , 2020, Neurology.
[31] Peter L Jones,et al. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy. , 2019, Annual review of genomics and human genetics.
[32] C. Banerji,et al. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level , 2019, Human molecular genetics.
[33] J. Statland,et al. Effects of weakness of orofacial muscles on swallowing and communication in FSHD , 2019, Neurology.
[34] G. Andersen,et al. Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy , 2019, Journal of Neurology.
[35] J. Statland,et al. Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy , 2019, Neurology.
[36] Simone Severini,et al. Dynamic transcriptomic analysis reveals suppression of PGC1/ERR drives perturbed myogenesis in facioscapulohumeral muscular dystrophy , 2018 .
[37] L. Kunkel,et al. Transgenic zebrafish model of DUX4 misexpression reveals a developmental role in FSHD pathogenesis , 2018, Human molecular genetics.
[38] C. Horlings,et al. Phenotype‐genotype relations in facioscapulohumeral muscular dystrophy type 1 , 2018, Clinical genetics.
[39] S. Tapscott,et al. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle. , 2018, Human molecular genetics.
[40] C. Nicoletti,et al. Denervation-activated STAT3–IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis , 2018, Nature Cell Biology.
[41] C. Horlings,et al. A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1 , 2018, Neurology.
[42] L. Bains,et al. Oxidative capacity varies along the length of healthy human tibialis anterior , 2018, The Journal of physiology.
[43] H. Lochmüller,et al. Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy , 2017, Muscle & nerve.
[44] E. Ricci,et al. Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy , 2018, Molecular Neurobiology.
[45] B. Engelen,et al. Early onset facioscapulohumeral dystrophy – a systematic review using individual patient data , 2017, Neuromuscular Disorders.
[46] Olivier Pourquié,et al. Making muscle: skeletal myogenesis in vivo and in vitro , 2017, Development.
[47] M. Buckingham. Gene regulatory networks and cell lineages that underlie the formation of skeletal muscle , 2017, Proceedings of the National Academy of Sciences.
[48] B. Engelen,et al. 225th ENMC international workshop: A global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands , 2017, Neuromuscular Disorders.
[49] A. Geurts,et al. Upper limb function and activity in people with facioscapulohumeral muscular dystrophy: a web-based survey , 2017, Disability and rehabilitation.
[50] N. Saunders,et al. DUX4 Is Derepressed in Late-Differentiating Keratinocytes in Conjunction with Loss of H3K9me3 Epigenetic Repression. , 2016, The Journal of investigative dermatology.
[51] C. Horlings,et al. What's in a name? The clinical features of facioscapulohumeral muscular dystrophy , 2016, Practical Neurology.
[52] A. Falini,et al. Muscle MRI findings in facioscapulohumeral muscular dystrophy , 2016, European Radiology.
[53] S. Tapscott,et al. Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies , 2015, Muscle & nerve.
[54] S. Tapscott,et al. Immunohistochemical Characterization of FacioscapulohumeralMuscular Dystrophy Muscle Biopsies , 2015, Journal of neuromuscular diseases.
[55] N. Voermans,et al. Facioscapulohumeral muscular dystrophy as a genetic cause of pectus excavatum. , 2015, European journal of medical genetics.
[56] O. King,et al. Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy , 2015, Clinical Epigenetics.
[57] S. Severini,et al. β-catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy , 2015, Journal of The Royal Society Interface.
[58] A. Geurts,et al. Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD , 2014, Neurology.
[59] O. King,et al. Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing , 2014, Clinical Epigenetics.
[60] A. Verbeek,et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy , 2014, Neurology.
[61] E. Mercuri,et al. Upper Girdle Imaging in Facioscapulohumeral Muscular Dystrophy , 2014, PloS one.
[62] F. Magdinier,et al. P.16.3 DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles , 2013, Neuromuscular Disorders.
[63] F. Sera,et al. Large scale genotype–phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy , 2013, Brain : a journal of neurology.
[64] T. Partridge. The mdx mouse model as a surrogate for Duchenne muscular dystrophy , 2013, The FEBS journal.
[65] L. Santoro,et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. , 2012, American journal of human genetics.
[66] A. Verrotti,et al. Epilepsy, speech delay, and mental retardation in facioscapulohumeral muscular dystrophy. , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[67] Raffaele Iorio,et al. CD8+ T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI , 2011, Journal of Clinical Immunology.
[68] Daniel G. Miller,et al. A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy , 2010, Science.
[69] G. Carnac,et al. Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects , 2008, Journal of cellular and molecular medicine.
[70] L. Kunkel,et al. Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers , 2009, Proceedings of the National Academy of Sciences.
[71] Mario Quarantelli,et al. Modifications of brain tissue volumes in facioscapulohumeral dystrophy , 2006, NeuroImage.
[72] K. Flanigan,et al. Sarcolemmal reorganization in facioscapulohumeral muscular dystrophy , 2006, Annals of neurology.
[73] R. Frants,et al. Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. , 2004, American journal of human genetics.
[74] M. Dorobek,et al. A severe case of facioscapulohumeral muscular dystrophy (FSHD) with some uncommon clinical features and a short 4q35 fragment. , 2004, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[75] L. Sandkuijl,et al. Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 repeat involved in facioscapulohumeral muscular dystrophy. , 2004, American journal of human genetics.
[76] E. Bakker,et al. Somatic mosaicism in FSHD often goes undetected , 2004, Annals of neurology.
[77] I. Nonaka,et al. Sarcolemmopathy: Muscular Dystrophies with Cell Membrane Defects , 2001, Brain pathology.
[78] L. Sandkuijl,et al. De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10. , 2000, American journal of human genetics.
[79] R. Griggs,et al. Monozygotic twins with facioscapulohumeral dystrophy (FSHD): Implications for genotype/phenotype correlation , 1995, Muscle & nerve. Supplement.
[80] I. Nonaka,et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): Immunocytochemical and genetic analyses , 1995, Muscle & nerve. Supplement.
[81] C. Wijmenga,et al. Facioscapulohumeral muscular dystrophy in the dutch population , 1995, Muscle & nerve. Supplement.
[82] C. Wijmenga,et al. The FSHD‐linked locus D4F104S1 (p13E‐11) ON 4q35 has a homologue on 10qter , 1995, Muscle & nerve. Supplement.
[83] E. Bakker,et al. Early onset facioscapulohumeral muscular dystrophy , 1995, Muscle & nerve. Supplement.
[84] J. Bodensteiner,et al. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies , 1978, Neurology.